Cardiff Oncology
CRDF
67 hedge funds and large institutions have $19.6M invested in Cardiff Oncology in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 32 closing their positions.
16% more call options, than puts
Call options by funds: $445K | Put options by funds: $385K
17.54% less ownership
Funds ownership: 38.16% → 20.62% (-18%)
26% less funds holding
Funds holding: 91 → 67 (-24)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
52% less capital invested
Capital invested by funds: $41M → $19.6M (-$21.3M)
69% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 32
Top Buyers
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$4.32M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.64M |
| 3 |
BlackRock
New York
|
-$3.06M |
| 4 |
State Street
Boston,
Massachusetts
|
-$945K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$792K |
CRDF Hedge Fund Activity: Q2 2022 in Review
67 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2022, worth a combined $19.6M — down 52% from $41M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CRDF and 10 opened new positions — a net loss of 22 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.21M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $4.32M sold.
- 67 institutional investors held Cardiff Oncology (CRDF) as of Q2 2022, down from 91 in Q1 2022.
- Funds reported $19.6M of Cardiff Oncology stock for Q2 2022, down 52% quarter-over-quarter.
- 10 funds opened new Cardiff Oncology positions in Q2 2022 and 32 closed out, a net change of -22 holders.
- The largest Cardiff Oncology buyer in Q2 2022 was Laurion Capital Management, an estimated $1.21M added.
- The largest Cardiff Oncology seller in Q2 2022 was Janus Henderson Group, an estimated $4.32M sold.
Based on aggregated 13F filings for Q2 2022.